Application for consistency evaluation of hydrochloric acid than astrolipid injection was accepted

　　Pharmaceutical Network May 9th, May 8th, Shimedicine Oyi Pharmaceuticals submitted hydrochloric acid polysofer than astrolipid injection consistency evaluation supplement application was accepted by CDE, the acceptance number is CYHB2050254 Minet data show that in 2019 China's public medical institutions terminal hydrochloric acid polysoft than star liposome injection sales of 3.413 billion yuan, an increase of 28.24% year-on-year, stone medicine for the product's first declared consistency evaluation enterprises hydrochloric acid polyshodria is an anti-tumor drug that can be used in patients with low CD4 (200CD4 lymphocytes/mm) and aids-related Capo's sarcoma (AIDS-KS) patients with extensive skin mucosa visceral This product is an improved version of hydrochloric acid polysoft than star, in the form of lipids to reduce the possibility of external infiltration damage, help to reduce Figure 1: 2015-2019 China's public medical institutions terminal hydrochloric acid polysicacid injection sales (units: 10,000 yuan) meters of the net data show that 2019 China's urban public , county-level public hospitals, urban community centers and townships Health Hospital (China's public medical institutions) terminal hydrochloric acid polysoft ratio star liposome injection sales of 3.413 billion yuan, an increase of 28.24% YoY, in the anti-
drug TOP10 varieties, with 3.53% of the market share ranked eighth Figure 2: 2019 China's public medical institutions terminal hydrochloric acid polyjumial than star liposome injection stoid manufacturers competition pattern
the current domestic market has 4 pharmaceutical enterprises (1 imported 3 domestic enterprises) with hydrochloric acid polysoft ratio star liposome injection production approval In 2019 China's public medical institutions terminal manufacturers competition pattern, Shipharma O'I pharmaceutical industry with 54.33 percent of the market share ranked first, Changzhou Jinyuan Pharmaceuticals with 31.54 percent of the market share, two pharmaceutical companies accounted for more than 80% of the market share meter net data show that the current hydrochloric acid polysoft than star liposome injection has not been evaluated by enterprises, stone medicine European-Italian pharmaceutical industry first submitted the product consistency evaluation supplementary application, is expected to be the first evaluation source: Internet database note: statistics as of May 8, if there are omissions, welcome to point the finger!